Jawaunna Blackmon

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The use of immunotherapy in the treatment of non-Hodgkin lymphomas has improved response rates and survival in this population. With widespread rituximab use and longer-term follow-up of patients receiving rituximab, infectious complications are increasing. These complications are of great concern in the AIDS-related lymphoma population. We review the data(More)
  • 1